Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3153292 | 0.92 | HTR6 (1.00) | HTR6 | |
| SCHEMBL4968803 | 0.92 | HTR6 (0.84) | HTR6POLB | |
| SCHEMBL3138888 | 0.90 | HTR6 (0.86) | HTR6 | |
| SCHEMBL3142976 | 0.88 | HTR6 (0.79) | HTR6 | |
| SCHEMBL3324172 | 0.88 | HTR6 (0.82) | HTR6 | |
| SCHEMBL3153146 | 0.85 | HTR6 (1.00) | HTR6 | |
| SCHEMBL4968171 | 0.83 | HTR6 (0.84) | HTR6 | |
| SCHEMBL13333259 | 0.81 | HTR6 (0.76) | HTR6MEN1KMT2A | |
| Morpholine SCHEMBL27750088 | 0.81 | HTR6 (0.69) | HTR6ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL3156785 | 0.81 | HTR6 (0.79) | HTR6ALDH1A1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081600-B1 | Combination of the NMDA- receptor ligand memantine and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2012-12-05 | — | — | EP | claimed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| EP-1666462-B1 | N-[1H-INDOL-5-YL]NAPHTHALENE-1-SULPHONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | ESTEVE LABOR DR (ES) | 2009-04-15 | — | — | EP | claimed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | claimed |
| WO-2009013010-A2 | 5HT6-LIGANDS SUCH AS SULFONAMIDE DERIVATIVES IN DRUG- INDUCED WEIGHT-GAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-01-29 | — | — | WO | claimed |
| EP-2018861-A1 | 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-28 | — | — | EP | claimed |
| CN-100441180-C | Use of sulfonamide derivatives as ligands for 5-ht6, in treatment of e.g. food ingestion disorder, obesity, bulimia, anorexia, cachexia and type ii diabetes | PARATEK PHARM INNC (ES) | 2008-12-10 | — | — | CN | claimed |
| EP-1626715-B1 | USE OF SULPHONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION | ESTEVE LABOR DR (ES) | 2008-09-10 | — | — | EP | claimed |
| US-7176200-B2 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2007-02-13 | — | — | US | claimed |
| JP-2006525972-A | — | — | 2006-11-16 | — | — | JP | claimed |
| CN-1271052-C | Sulfonamide derivatives, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2006-08-23 | — | — | CN | claimed |
| CN-1816334-A | Use of sulfonamide derivatives as ligands for 5-ht6, in treatment of e.g. food ingestion disorder, obesity, bulimia, anorexia, cachexia and type ii diabetes | PARATEK PHARM INNC (ES) | 2006-08-09 | — | — | CN | claimed |
| EP-1666462-A1 | N-[1H-INDOL-5-YL]NAPHTHALENE-1-SULPHONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-06-07 | — | — | EP | claimed |
| EP-1626715-A1 | USE OF SULPHONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-22 | — | — | EP | claimed |
| US-20050065202-A1 | Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-03-24 | — | — | US | claimed |
| CN-1599718-A | Sulphonamide derivatives, the preparation thereof and the application of same as medicaments | ESTEVE LABOR DR (ES) | 2005-03-23 | — | — | CN | claimed |
| WO-2004098588-A1 | USE OF SULPHONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2004-11-18 | — | — | WO | claimed |
| EP-1445252-A1 | SULPHONAMIDE DERIVATIVES, THE PREPARATION THEREOF AND THE APPLICATION OF SAME AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-08-11 | — | — | EP | claimed |
| US-20030191124-A1 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2003-10-09 | — | — | US | claimed |
| EP-2081600-B1 | Combination of the NMDA- receptor ligand memantine and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2012-12-05 | — | — | EP | disclosed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-03-25 | — | — | US | disclosed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| CN-101563106-A | Combination of nmda- receptor ligand and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2009-10-21 | — | — | CN | disclosed |
| CN-101500611-A | Combination of a cholinesterase inhibitor and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2009-08-05 | — | — | CN | disclosed |
| EP-2081600-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-07-29 | — | — | EP | disclosed |
| EP-1660131-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2009-06-24 | — | — | EP | disclosed |
| EP-1666462-B1 | N-[1H-INDOL-5-YL]NAPHTHALENE-1-SULPHONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | ESTEVE LABOR DR (ES) | 2009-04-15 | — | — | EP | disclosed |
| EP-2040755-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-04-01 | — | — | EP | disclosed |
| US-7498328-B2 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIAS DEL DR. ESTEVE, S.A. (ES) | 2009-03-03 | — | — | US | disclosed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | disclosed |
| EP-2018861-A1 | 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain | Laboratorios del Dr. Esteve S.A. (ES) | 2009-01-28 | — | — | EP | disclosed |
| CN-100441180-C | Use of sulfonamide derivatives as ligands for 5-ht6, in treatment of e.g. food ingestion disorder, obesity, bulimia, anorexia, cachexia and type ii diabetes | PARATEK PHARM INNC (ES) | 2008-12-10 | — | — | CN | disclosed |
| US-7452881-B2 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2008-11-18 | — | — | US | disclosed |
| EP-1648468-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2008-09-24 | — | — | EP | disclosed |
| EP-1626715-B1 | USE OF SULPHONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION | ESTEVE LABOR DR (ES) | 2008-09-10 | — | — | EP | disclosed |
| WO-2008034815-A1 | COMBINATION OF NMDA- RECEPTOR LIGAND AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-27 | — | — | WO | disclosed |
| EP-1902733-A1 | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | disclosed |
| US-20070167448-A1 | Such as N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide; serotonin receptors antagonist; anxiolytic, antidepressant, cognitive activator, senile dementia, psychosis, attention deficit/hyperactivity disorder | MERCE-VIDAL RAMON | 2007-07-19 | — | — | US | disclosed |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-03-15 | — | — | US | disclosed |
| US-7176200-B2 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2007-02-13 | — | — | US | disclosed |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-11 | — | — | US | disclosed |
| US-20060258653-A1 | Derivatives of sulphonamides, their preparation and use as medicaments | MERCE-VIDAL RAMON | 2006-11-16 | — | — | US | disclosed |
| US-7105515-B2 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2006-09-12 | — | — | US | disclosed |
| CN-1271052-C | Sulfonamide derivatives, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2006-08-23 | — | — | CN | disclosed |
| CN-1816334-A | Use of sulfonamide derivatives as ligands for 5-ht6, in treatment of e.g. food ingestion disorder, obesity, bulimia, anorexia, cachexia and type ii diabetes | PARATEK PHARM INNC (ES) | 2006-08-09 | — | — | CN | disclosed |
| EP-1666462-A1 | N-[1H-INDOL-5-YL]NAPHTHALENE-1-SULPHONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS SEROTONIN 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-06-07 | — | — | EP | disclosed |
| EP-1660131-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-05-31 | — | — | EP | disclosed |
| EP-1648468-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| EP-1626715-A1 | USE OF SULPHONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-02-22 | — | — | EP | disclosed |
| US-20050065202-A1 | Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2005-03-24 | — | — | US | disclosed |
| CN-1599718-A | Sulphonamide derivatives, the preparation thereof and the application of same as medicaments | ESTEVE LABOR DR (ES) | 2005-03-23 | — | — | CN | disclosed |
| WO-2005014000-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014045-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | disclosed |
| US-20050032791-A1 | Such as N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide for treating anxiety, depression, cognitive memory disorders and senile dementia, psychosis, infant hyperkinesia (ADHD, attention deficit/hyperactivity disorder) | MERC-VIDAL RAMON (ES) | 2005-02-10 | — | — | US | disclosed |
| WO-2004098588-A1 | USE OF SULPHONAMIDE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS AND/OR TREATMENT OF DISORDERS OF FOOD INGESTION | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2004-11-18 | — | — | WO | disclosed |
| EP-1445252-A1 | SULPHONAMIDE DERIVATIVES, THE PREPARATION THEREOF AND THE APPLICATION OF SAME AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-08-11 | — | — | EP | disclosed |
| US-20030191124-A1 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2003-10-09 | — | — | US | disclosed |
| US-20030191124-A1 | Derivatives of sulphonamides, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065202-A1 | Use of sulphonamide derivatives for the manufacture of a medicament for the prophylaxis and/or treatment of disorders of food ingestion | SULT2A1, STS, MPST | HTR6 886/4885ALDH1A1 1018/4885MEN1 887/4885 |
| US-20070059364-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | HTR6, NPY5R, NPY2R | HTR6 1/4885ALDH1A1 3499/4885MEN1 1677/4885 |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | HTR6, HTR3B, HTR4 | HTR6 1/4885ALDH1A1 1409/4885MEN1 2057/4885 |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | HTR6 1/4885ALDH1A1 1189/4885MEN1 2263/4885 |
| US-20070167448-A1 | Such as N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide; serotonin receptors antagonist; anxiolytic, antidepressant, cognitive activator, senile dementia, psychosis, attention deficit/hyperactivity disorder | HTR1A, HTR6, HTR4 | HTR6 2/4885ALDH1A1 575/4885MEN1 4761/4885 |
| US-20050032791-A1 | Such as N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide for treating anxiety, depression, cognitive memory disorders and senile dementia, psychosis, infant hyperkinesia (ADHD, attention deficit/hyperactivity disorder) | CHAT, SLC6A3, PSEN2 | HTR6 10/4885ALDH1A1 416/4885MEN1 4836/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | HTR6 1/4885ALDH1A1 3499/4885MEN1 1677/4885 |
| US-20100074955-A1 | Combination of NMDA-Receptor Ligand and a Compound With 5-HT6 Receptor Affinity | GRM6, GRIN3B, GRIN3A | HTR6 4/4885ALDH1A1 3257/4885MEN1 1091/4885 |
| US-20070009597-A1 | Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity | NPY5R, HTR6, NPY2R | HTR6 2/4885ALDH1A1 3880/4885MEN1 1861/4885 |
| US-20060258653-A1 | Derivatives of sulphonamides, their preparation and use as medicaments | STS, SULT2A1, MPST | HTR6 3170/4885ALDH1A1 620/4885MEN1 3173/4885 |
| US-20030191124-A1 | Derivatives of sulphonamides, their preparation and use as medicaments | STS, SULT2A1, MPST | HTR6 3229/4885ALDH1A1 475/4885MEN1 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.